Αρχική World News Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone... World News Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC Από Ogkologos - 14 Ιουλίου, 2025 918 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The most important cancer research stories of 2022 14 Δεκεμβρίου, 2022 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... 16 Ιουλίου, 2018 Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... 26 Νοεμβρίου, 2019 Whipple Procedure for Pancreatic Cancer: How to Prepare and What to... 16 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS “I feel extremely proud when I look at what we’ve achieved”: ScottishPower’s Andrew... Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... 4 Steps We Can All Take on World Cancer Day to...